Guide de réussite

1) personne contact parmi le groupe ou un partenaire: [email protected] 2) adresse URL si disponible : http://www.pandamrcdesmoulins.org/static/documentation/2014-03-31/JournalDeBord.pdf et http://www.pandamrcdesmoulins.org/static/documentation/2014-03-31/Manuel.pdf 3) partenaires ayant participé au projet - Groupe Panda MRC des MoulinsTravail réalisé dans le cadre du cours PHA2415L’objectif de notre projet est la création d’un journal de bord pour les enfants atteints de TDAH afin de faciliter la communication entre les parents et les enseignants et permettre un meilleur suivi de ce trouble par les médecins. Le journal a été créé pour les enfants de niveau primaire et l’intervention s’adressait aux parents et enseignants de ces enfants

A Conserved Target Site in HIV-1 Gag RNA is Accessible to Inhibition by Both an HDV Ribozyme and a Short Hairpin RNA

Antisense-based molecules targeting HIV-1 RNA have the potential to be used as part of gene or drug therapy to treat HIV-1 infection. In this study, HIV-1 RNA was screened to identify more conserved and accessible target sites for ribozymes based on the hepatitis delta virus motif. Using a quantitative screen for effects on HIV-1 production, we identified a ribozyme targeting a highly conserved site in the Gag coding sequence with improved inhibitory potential compared to our previously described candidates targeting the overlapping Tat/Rev coding sequence. We also demonstrate that this target site is highly accessible to short hairpin directed RNA interference, suggesting that it may be available for the binding of antisense RNAs with different modes of action. We provide evidence that this target site is structurally conserved in diverse viral strains and that it is sufficiently different from the human transcriptome to limit off-target effects from antisense therapies. We also show that the modified hepatitis delta virus ribozyme is more sensitive to a mismatch in its target site compared to the short hairpin RNA. Overall, our results validate the potential of a new target site in HIV-1 RNA to be used for the development of antisense therapies